Document Information [Line Items]
Document type
Amendment flag
Document period end date
Amendment description
Entity common stock shares outstanding
Entity Listings [Line Items]
Entity Listings, Instrument [Axis]
Instrument [Domain]
Entity Listings [Table]
Entity [Text Block]
Entities [Table]
Entity Information [Line Items]
Entity registrant name
Entity central index key
Current fiscal year end date
Entity well known seasoned issuer
Entity voluntary filers
Entity current reporting status
Entity filer category
Entity public float
Income Statement [Abstract]
Statement [Table]
Statement Scenario [Axis]
Statement [Line Items]
Statement of Financial Position [Abstract]
Statement of Cash Flows [Abstract]
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest [Abstract]
Income (Loss) from Continuing Operations, Including Portion Attributable to Noncontrolling Interest [Abstract]
Costs and expenses:
Revenues Abstract
Cost of sales
Restructuring Charges And Acquisition Related Costs
Selling, informational and administrative expenses
Research and development expenses
Amortization of intangible assets
Less: Net income attributable to noncontrolling interests
Net income attributable to Pfizer Inc.
Net income before allocation to noncontrolling interests
Discontinued operations - net of tax total
Income from continuing operations
Provision for taxes on income
Earnings Per Share Attributable to Common Shareholders [Abstract]
Earnings per common share - diluted:
Earnings per common share - basic:
Diluted (in shares)
Basic (in shares)
Cash dividends paid per common share (in dollars per share)
Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)
Discontinued operations - net of tax (in dollars per share)
EPS Basic
Net income attributable to Pfizer Inc. common shareholders [Diluted]
Discontinued operations - net of tax [Diluted]
Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)
Basis of Presentation [Text Block]
Comprehensive Income (Expense) [Text Block]
Inventories [Text Block]
Goodwill and Other Intangible Assets [Text Block]
Pension and Postretirement Benefit Plans [Text Block]
Earnings Per Share Attributable to Common Shareholders [Text Block]
Segment, Product and Geographic Information [Text Block]
Assets
Liabilities and Shareholders' Equity
Total liabilities and shareholders' equity
Liabilities [Abstract]
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]
Total assets
Total liabilities
Inventories
Short-term loans
Accounts receivable, less allowance for doubtful accounts
Short-term investments
Cash and cash equivalents
Total current assets
Long-term investments and loans
Property, plant and equipment, less accumulated depreciation
Goodwill
Total identifiable intangible assets, less accumulated amortization
Short-term borrowings, including current portion of long-term debt
Accounts payable
Dividends payable
Income taxes payable
Accrued compensation and related items
Total current liabilities
Long-term debt
Pension benefit obligations
Postretirement benefit obligations
Noncurrent deferred tax liabilities
Other noncurrent liabilities
Total Pfizer Inc shareholders' equity
Common stock
Additional paid-in capital
Employee benefit trust, at fair value
Treasury stock
Retained earnings
Accumulated other comprehensive loss
Preferred stock
Equity attributable to noncontrolling interests
Total shareholders' equity
Cash and Cash Equivalents, Period Increase (Decrease) [Abstract]
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period
Revenues
Income from continuing operations before provision for taxes on income
Assets held for sale
Acquisition of King Pharmaceuticals Inc [Text Block]
Cash (refunded)/paid for income taxes
Cash paid for interest
Supplemental Cash Flow Information:
Net decrease in cash and cash equivalents
Operating Activities:
Investing Activities:
Financing Activities:
Share-based compensation expense
Depreciation and amortization
Deferred taxes from continuing operations
Net cash provided by operating activities
Purchases of property, plant and equipment
Purchases of short-term investments
Purchases of long-term investments
Other investing activities
Net cash used in investing activities
Principal payments on long-term debt
Cash dividends paid
Net cash (used in)/provided by financing activities
Effect of exchange-rate changes on cash and cash equivalents
Income from continuing operations attributable to Pfizer Inc. common shareholders [Dilluted]
Discontinued operations - net of tax (in dollars per share)
Net income attributable to Pfizer Inc. common shareholders (in dollars per share)
Treasury stock
Accumulated other comprehensive expense
Purchases of property, plant and equipment
Purchases of short-term investments
Purchases of long-term investments
Other investing activities
Principal payments on long-term debt
Cash dividends paid
Other taxes payable
Repayments Of Short Term Debt Maturing In More Than Three Months Net Of Repayments Of Short Term Debt Maturing In Three Months Or Less
Principal payments on short-term borrowings, net
Changes in assets and liabilities, net of acquisitions and divestitures
The cash outflow from a repayment of a borrowing having initial term of repayment of more than three months but less than one year or one operating cycle (if the normal cycle is more than one year) and may include the cash outflow from a repayment of a borrowing having initial term of repayment within three months net of the cash inflow of a borrowing having initial term of repayment within three months.
Discontinued operations - net of tax
This element represents (i) restructuring charges, which are amounts charged against earnings in the period for incurred and estimated costs associated with exit from or disposal of business activities or restructurings pursuant to a program that is planned and controlled by management, and materially changes either the scope of a business undertaken by an entity, or the manner in which that business is conducted; and (ii) acquisition-related costs, which are costs incurred to effect a business combination which costs have been expensed during the period. Such costs can include transaction costs such as banking, legal, accounting and other costs directly related to effect a business combination as well as external, incremental costs of integration planning that are directly related to a business combination, including costs associated with preparing for systems and other integration activities.
Income from continuing operations before provision for taxes on income
Income from continuing operations
Net income before allocation to noncontrolling interests
Net income attributable to Pfizer Inc.
Net income attributable to Pfizer Inc. common shareholders (in dollars per share)
Total current assets
Total assets
Total current liabilities
Total liabilities
Total Pfizer Inc. shareholders' equity
Total shareholders' equity
Total liabilities and shareholders' equity
Net cash provided by/(used in) operating activities
Net cash provided by investing activities
Net cash used in financing activities
Employee benefit trusts
Other financing activities
Other changes in assets and liabilities, net of acquisitions and divestitures
Document fiscal year focus
Document fiscal period focus
Document Information [Table]
Legal Entity [Axis]
Entity [Domain]
Parent Company [Member]
Restructuring charges and certain acquisition-related costs
Current deferred tax liabilities and other current liabilities
This element represents (i) the current portion of deferred tax liabilities, which result from applying the applicable tax rate to net taxable temporary differences pertaining to each jurisdiction to which the entity is obligated to pay income tax. A current taxable temporary difference is a difference between the tax basis and the carrying amount of a current asset or liability in the financial statements prepared in accordance with generally accepted accounting principles. In a classified statement of financial position, an enterprise shall separate deferred tax liabilities and assets into a current amount and a noncurrent amount. Deferred tax liabilities and assets shall be classified as current or noncurrent based on the classification of the related asset or liability for financial reporting. A deferred tax liability or asset that is not related to an asset or liability for financial reporting, including deferred tax assets related to carryforwards, shall be classified according to the expected reversal date of the temporary difference; and (ii) the aggregate carrying amount, as of the balance sheet date, of current obligations not separately disclosed in the balance sheet due to materiality considerations. Current liabilities are expected to be paid within one year (or the normal operating cycle, if longer).
Cost Reduction Initiatives And Acquisition Related Costs Disclosure [Text Block]
Costs Associated with Cost-Reduction Initiatives and Acquisition Activity [Text Block]
Comprehensive Income/(Loss) [Text Block]
Taxes on Income [Text Block]
Net decrease in cash and cash equivalents
Description of cost-reduction initiatives associated with a comprehensive plan to integrate acquired operations, generate cost savings and capture synergies across the company; as well as costs incurred in connection with an acquisition. These costs include (i) restructuring activities, including exit and disposal activities, the major types of costs associated with the plan activities and the accrual balance at the end of the period; (ii) integration costs, which represent external, incremental costs directly related to integrating acquired businesses; (iii) implementation costs, which represent external, incremental costs directly related to implementing cost-reduction initiatives prior to the Wyeth acquisition and primarily include expenditures related to system and process standardization and the expansion of shared services; (iv) additional depreciation-asset restructuring, which represents the impact of changes in the estimated useful lives of assets involved in restructuring actions; and (v) transaction costs, representing external costs incurred in connection with an acquisition.
Comprehensive Income/(Loss) [Abstract]
Acquisition Purchase Price
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Working Capital Excluding Inventories
Working capital, excluding inventories
InventoriesAcquisition
Property, plant and equipment
The amount of working capital, excluding inventories, recognized as of the acquisition date.
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Net Tax Accounts
Net tax accounts
The amount of net tax accounts recognized as of the acquisition date.
Total identifiable net assets
Total identifiable net assets
Net assets acquired
Net assets acquired/total consideration transferred
Inventories
Schedule of restructuring charges [Text Block]
Schedule of costs in connection with cost-reduction initiatives and the acquisition of Wyeth.
Cost Reduction Initiatives and Acquisition Related Costs [Table]
Cost reduction initiatives and acquisition costs [Line Items]
Additional Depreciation Asset Restructuring
Additional depreciation asset restructuring represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.
Implementation Costs
Total implementation costs
Implementation costs represent external, incremental costs directly related to Implementing cost-reduction initiatives, and primarily include expenditures related to system and process standardization and the expansion of shared services.
Cost Reduction Initiatives And Acquisition Costs
Total costs incurred in connection with Pfizer's cost-reduction initiatives and the acquisition of Wyeth.
Cost Reduction Initiatives and Acquisition Costs of Wyeth [Abstract]
Total costs associated with cost-reduction initiatives and acquisition activity
Footnote information [Abstract]
Asset impairments [Member]
Other Restructuring Charges [Member]
Employee termination costs [Member]
Other [Member]
Costs Incurred
Activity
Accrual
Restructuring Charges [Member]
Restructuring charges abstract
Estimated Employee Terminations
Actual Employees Terminated
Business Acquisition [Line Items]
Business Acquisition Purchase Price
Additional depreciation asset restructuring [Member]
Total additional depreciation-asset restructuring
Restructuring and related costs by type [Axis]
Types of restructuring [Domain]
Schedule of gains (losses) on interest rate risk [Text Block]
Trading securities [Member]
Available - for - sale money market funds [Member]
Available - for - sale equity securities, excluding money market funds [Member]
Foreign currency swaps [Member]
Interest rate swaps [Member]
Foreign currency forward-exchange contracts [Member]
Fair Value Assets Measured on Recurring Basis [Domain]
Other selected financial assets [Abstract]
Other Selected Financial Assets
Total
Other Financial Liabilities
Total
Footnotes to selected financial assets and liabilities [Abstract]
Selected financial assets and liabilities presented in the condensed consolidated balance sheets [Line Items]
Cash and cash equivalents at fair value
Fair value inputs Level 1 [Member]
Selected Financial Liabilities Current Deferred Tax Liabilities And Other Current Liabilities
Other current liabilities
Selected financial liabilities presented in the balance sheet caption, Current deferred tax liabilities and other current liabilities, at the balance sheet date.
Selected Financial Liabilities Other Noncurrent Liabilities
Other noncurrent liabilities
Selected financial liabilities presented in the balance sheet caption, Other Noncurrent liabilities, at the balance sheet date.
Fair Value By Balance Sheet Grouping [Axis]
Fair Value Disclosure Items [Domain]
Investments in Debt and Equity Securities [Abstract]
Debt Securities
This item represents the total of all debt securities grouped by maturity dates.
Total debt securities
Available For Sale Securities Equity Securities Money Market Funds
Available - for - sale money market funds
This item represents equity securities categorized neither as held-to-maturity nor trading. Money market funds represent ownership in debt instruments. If money markets funds are determined to have had an other than temporary decline in fair value below its amortized cost basis the loss loss shall be recognized in earnings.
Available - for - sale securities equity securities, excluding money market funds
Available - for - sale equity securities, excluding money market funds
This item represents equity securities excluding money market funds categorized neither as held-to-maturity nor trading. Equity securities excluding money market funds represent ownership interests or the right to acquire ownership interests in corporations and other legal entities which ownership interest is represented by shares of common or preferred stock (which is not mandatorily redeemable or redeemable at the option of the holder), convertible securities, stock rights, or stock warrants. Unrealized gains and losses related to Available-for-sale Securities are excluded from earnings and reported in a separate component of shareholders' equity (other comprehensive income), unless the Available-for-sale Security is designated as a hedge or is determined to have had an other than temporary decline in fair value below its amortized cost basis. All or a portion of the unrealized holding gain or loss of an Available-for-sale Security that is designated as being hedged in a fair value hedge shall be recognized in earnings during the period of the hedge, as should other than temporary declines in fair value below costs basis.
Schedule of available - for - sale securities [Axis]
Major Types of Debt and Equity Securities [Domain]
Securities (Assets) [Member]
Debt Securities [Member]
Western European and other government debt [Member]
Western European and other government agency debt [Member]
Supranational debt [Member]
Represents the debt of international organizations such as the World Bank, the International Monetary Fund, regional multilateral development banks, multilateral financial institutions, and other similar organizations.
Certificates of deposit [Member]
Corporate debt [Member]
Federal Home Loan Mortgage Corporation And Federal National Mortgage Association Asset Backed Securities [Member]
This category includes investments in asset-backed debt securities issued by the Federal Home Loan Mortgage Corporation and Federal National Mortgage Association.
Reverse repurchase agreements [Member]
Schedule of held - to - maturity debt securities [Axis]
Major Types of Debt Securities [Domain]
Certificates of deposit and other [Member]
This category includes information about certificates of deposit and other held to maturity debt securities not separately identified.
Short - Term Borrowings [Abstract]
Commercial paper
Senior unsecured notes at fair value
Derivative Financial Instruments and Hedging Activities
Cash and cash equivalents
Senior unsecured notes
Major Types of Debt Securities [Domain]
Foreign Currency Debt Designated As Hedging Instruments Long Term Liability At Fair Value [Member]
Foreign Currency Borrowings Designated As Hedging Instruments Short Term Liability At Fair Value [Member]
Available - for - sale debt securities:
Held - to - maturity debt securities:
Available - for - sale debt securities maturities within 1 year
Available - for - sale debt securities maturities over 1 to 5 years
Long-term loans, carried at cost
Short - term borrowings
Commercial Paper [Member]
Credit Risk
Collateral received
Other comprehensive income/(loss):
Net unrealized (losses)/gains on derivative financial instruments
Net unrealized losses on available - for - sale securities
Benefit plan adjustments
Total comprehensive (loss) income before allocation to noncontrolling interests
Less: Comprehensive income/(loss) attributable to noncontrolling interests
Comprehensive (loss) income attributable to Pfizer Inc.
Total comprehensive income/(loss) before allocation to noncontrolling interests
Comprehensive income/(loss) attributable to Pfizer Inc.
Total inventories
Finished goods
Work - in - process
Raw materials and supplies
Schedule of changes in carrying amount of goodwill [Text Block]
Statement Business Segments [Axis]
Segment [Domain]
Changes in the carrying amount of goodwill
Balance, December 31, 2010
Text block covering the Disclosure of the details of finite-lived and indefinite-lived intangible assets, excluding goodwill, in total and by major class. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.
Balance, April 3, 2011
Finite-Lived Intangible Assets by Major Class [Axis]
Developed technology rights [Member]
Finite-Lived Intangible Assets, Major Class Name [Domain]
Licensing Agreements [Member]
Brands [Member]
Finite-lived intangible assets
Finite lived intangible assets gross carrying amount
Gross Carrying Amount
Finite lived intangible assets accumulated amortization
Accumulated Amortization
Finite lived intangible assets net
Identifiable Intangible Assets, less Accumulated Amortization
Indefinite-lived Intangible Assets By Major Class [Axis]
Indefinite-lived Intangible Assets, Major Class [Domain]
Indefinite-lived intangible assets
Indefinite-lived intangible assets excluding goodwill
Indefinite - lived brands
Indefinite - lived In-process research and development
Indefinite-lived trademarks
Carrying amount as of the balance sheet date for in-process research and development. In-process research and development assets that have not yet received regulatory approval and are required to be classified as indefinite- lived assets until the successful completion or the abandonment of the associated research and development effort. During the development period after acquisition, these assets will not be amortized until approval is obtained.
Carrying amount as of the balance sheet date for brands. Brands represent the amortized or unamortized cost associated with tradenames and know-how, as the products themselves no longer receive patent protection.
The rights acquired through registration of a brand name to gain or protect exclusive use thereof.
Goodwill and Other Intangible Assets Narrative [Abstract]
Amortization expense for finite-lived intangible assets
Aggregate notional amount of interest rate derivative financial instruments
Derivatibe Instruments, Gain (Loss) by Hedging Relationship [Axis]
Hedging Relationship [Domain]
Fair Value Hedging [Member]
Cash Flow Hedging [Member]
Net Investment Hedging [Member]
Nondesignated [Member]
Gains losses incurred to hedge or offset operational foreign exchange or interest rate risk [Abstract]
Recognized in OID
Recognized in OCI
Reclassified from OCI to OID
Derivative Instruments Gain (Loss) by Derivative Instrument Risk [Axis]
Foreign currency short - term borrowings [Member]
Foreign currency long - term debt [Member]
Derivative Contract Type [Domain]
Non - Derivative Financial Instruments in Net Investment Hedge Relationships [Abstract]
Financial Instruments Narrative [Abstract]
Posted collateral
Additional collateral
Selected Financial Assets
Selected Financial Liabilities
United States Supplemental Non Qualified Pension Plans Of U S Entity Defined Benefit [Member]
U.S. Qualified [Member]
International [Member]
U.S. Supplemental (Non-Qualified) [Member]
Defined Benefit Plans Disclosures Defined Benefit Plans [Axis]
Defined Benefit Plans [Domain]
Pension Plans Defined Benefit [Member]
Other Postretirement Benefit Plans Defined Benefit [Member]
Postretirement Plans [Member]
Amortization of: [Abstract]
Service cost
Interest cost
Expected return on plan assets
Prior service credits
Curtailments and settlements - net
Net periodic benefit costs
Pension and Postretirement Benefit Plans Narrative [Abstract]
Contributions
Expected contributions in next fiscal year
Special termination benefits
Net periodic benefit costs
Total indefinite-lived intangible assets
Income from continuing operations attributable to Pfizer Inc.
Net income attributable to Pfizer Inc. common shareholders
Net income attributable to Pfizer Inc. common shareholders and assumed conversions
Weighted - average number of common shares outstanding - Basic
EPS Numerator - Basic:
EPS Numerator - Diluted:
Common share equivalents: stock options, stock issuable under employee compensation plans and convertible preferred stock
Weighted - average number of common shares outstanding - Diluted
Stock options that had exercise prices greater than the average market price of our common stock issuable under employee compensation plans
Eps Numerator Diluted Abstract
Effective tax rate
Schedule of Segment Reporting Information by Segment [Text Block]
Schedule of Revenue by Products [Text Block]
Segment Revenues and Profit Loss [Abstract]
Segment profit / loss
Segment Revenues and Profit Loss Narrative [Abstract]
Net Interest Income Expense
Net interest expense/(income)
Products [Domain]
Capsugel [Member]
Enbrel [Member]
Lyrica [Member]
Effexor [Member]
Celebrex [Member]
Prevnar Prevenar 7 [Member]
Viagra [Member]
Xalatan / Xalacom [Member]
Norvasc [Member]
Zyvox [Member]
Prevnar / Prevenar 13 [Member]
Zosyn / Tazocin [Member]
Detrol Detrol L A [Member]
Sutent [Member]
Premarin family [Member]
Geodon / Zeldox [Member]
Genotropin [Member]
Chantix / Champix [Member]
Vfend [Member]
Caduet [Member]
Zithromax / Zmax [Member]
Re Facto A F Xyntha [Member]
All other [Member]
Alliance revenues [Member]
Zoloft [Member]
Revatio [Member]
Medrol [Member]
Cardura [Member]
Significant product revenues are as follows:
Entity - Wide Disclosure on Geographic Areas, Revenue from External Customers Attributed to Individual Foreign Countries [Axis]
Segment, Geographical [Domain]
Revenue by geographic area - United States
Revenue by geographic area - Foreign Countries
The percentage change in revenue attributed to foreign countries.
Total Revenues
Implementation costs [Member]
Restructuring Accrual [Member]
Intangible assets, gross carrying amount
Expected return on plan assets
Special termination benefits
Percentage Change in Revenue - Foreign Countries
Percentage Change In Revenue - United States
Percentage Change In Revenue
The gross carrying amount of all identifiable intangible assets for the period ended.
The percentage change in revenue attributed to the entity's country of domicile.
The percentage change in revenue.
Total selected financial assets at the balance sheet date.
Total selected financial liabilities.
Total selected financial assets
Total selected financial liabilities
Amount of net interest income and expense.
Restructuring charges and implementation costs associated with Pfizer's cost-reduction initiatives.
Total other financial liabilities
Item represents the expected reduction of the workforce due to cost-reduction initiatives.
Item represents the number of employees terminated due to cost-reduction initiatives.
Current deferred tax liabilities and other current liabilities
Other noncurrent liabilities
Costs Associated with Cost-Reduction Initiatives and Acquisition Activity
Footnote information
Restructuring charges:
Current deferred tax liabilities and other current liabilities
Other noncurrent liabilities
Other selected financial assets
Footnotes to selected financial assets and liabilities
Selected financial assets and liabilities presented in the condensed consolidated balance sheets
Liabilities
Short - Term Borrowings
Investments in Debt and Equity Securities
Gains / (losses) incurred to hedge or offset foreign exchange or interest rate risk
Non - Derivative Financial Instruments in Net Investment Hedge Relationships
Financial Instruments Narrative
Goodwill and Other Intangible Assets Narrative
Restructuring and acquisition - related costs
Amortization of:
Pension and Postretirement Benefit Plans Narrative
Segment Revenues and Profit Loss
Segment Revenues and Profit Loss Narrative
Goodwill [Line Items]
Revenues
Total other comprehensive loss
Total other comprehensive income/(loss)
Amounts Recognized as of Acquisition Date (provisional) [Member]
Measurement Period Adjustments [Member]
Amounts Recognized as of Acquisition Date, As Adjusted [Domain]
Business Combination Acquisition Related Costs Transaction Costs
This element represents external costs directly related to effecting a business combination which costs have been expensed during the period. Such costs include advisory, legal, accounting, valuation, and other similar services.
Transaction costs
Actuarial losses
Total profit
Total revenues
Actuarial losses
Business Acquisition [Axis]
Business Acquisition Acquiree [Domain]
Net income attributable to Pfizer Inc. common shareholders EPS
Net income attributable to Pfizer Inc. common shareholders
Goodwill [Table]
Schedule of Inventories [Table]
Inventories [Table]
Schedule of Indefinite-lived and Finite-lived Intangible Assets [Table]
Schedule of Defined Benefit Plans Disclosures [Table]
Defined Benefit Plan Disclosure [Line Items]
Schedule of Earnings Per Share Basic and Diluted by Common Class [Table]
Schedule of Segment Reporting Information by Segment [Table]
Segment Reporting Information [Line Items]
Schedule of Available for sale Securities and Held to maturity Securities [Table]
Derivative Instruments, Gain (Loss) by Hedging Relationship, by Income Statement Location, by Derivative Instrument Risk [Table]
Schedule of Comprehensive Income (Loss) [Table]
Income Taxes [Line Items]
Income Taxes [Table]
Derivative Instruments Gain (Loss) [Line Items]
Schedule of Available for sale Securities and Held to maturity Securities [Line Items]
Inventories [Line Items]
Schedule of Earnings Per Share Basic and Diluted [Line Items]
Schedule of Comprehensive Income [Line Items]
Schedule Of Cost Reduction Initiatives And Acquisition Related Costs Text Block
Schedule of costs in connection with cost-reduction initiatives and acquisition activity [Text Block]
Schedule of identifiable intangible assets [Text Block]
Goodwill Acquired During Period
Additions
Selected Financial Assets And Liabilities By Balance Sheet Grouping [Text Block]
This item represents the locations of selected financial assets and liabilities by balance sheet grouping at the balance sheet date.
Selected financial ssets and liabilities presented in the condensed consolidated balance sheets [Text Block]
This item represents equity securities categorized neither as held-to-maturity nor trading. Money market funds represent ownership in debt instruments. If money markets funds are determined to have had an other than temporary decline in fair value below its amortized cost basis the loss loss shall be recognized in earnings.
This item represents equity securities excluding money market funds categorized neither as held-to-maturity nor trading. Equity securities excluding money market funds represent ownership interests or the right to acquire ownership interests in corporations and other legal entities which ownership interest is represented by shares of common or preferred stock (which is not mandatorily redeemable or redeemable at the option of the holder), convertible securities, stock rights, or stock warrants. Unrealized gains and losses related to Available-for-sale Securities are excluded from earnings and reported in a separate component of shareholders' equity (other comprehensive income), unless the Available-for-sale Security is designated as a hedge or is determined to have had an other than temporary decline in fair value below its amortized cost basis. All or a portion of the unrealized holding gain or loss of an Available-for-sale Security that is designated as being hedged in a fair value hedge shall be recognized in earnings during the period of the hedge, as should other than temporary declines in fair value below costs basis.
This category includes information about debt securities (such as bonds) issued by political subdivisions.
The carrying value of securities purchased to be resold in reverse repurchase transactions.
Held To Maturity Securities Debt Maturities Net Carrying Amount
Held - to - maturity debt securities, carried at amortized cost
Selected Financial Assets Cash And Cash Equivalents
Cash and cash equivalents
Selected Financial Assets Long Term Investments And Loans
Long-term investments and loans
Selected Financial Assets Current Deferred Tax Assets And Other Current Assets
Taxes and other current assets
Selected Financial Assets Noncurrent Deferred Tax Assets And Other Noncurrent Assets
Taxes and other noncurrent assets
Selected financial assets presented in the balance sheet caption, Cash and cash equivalents, at the balance sheet date.
Selected financial assets presented in the balance sheet caption, Long-term investments and loans, at the balance sheet date.
Selected financial assets presented in the balance sheet caption, Current deferred tax assets and other current assets, at the balance sheet date.
Selected financial assets presented in the balance sheet caption, Noncurrent deferred tax assets and other noncurrent assets, at the balance sheet date.
Other asset-backed securities [Member]
Held-to-maturity Securities, Debt Maturities, within One Year, Net Carrying Amount
Held - to - maturity debt securities maturities within 1 year
Held-to-maturity Securities, Debt Maturities, after One Through Five Years, Net Carrying Amount
Held - to - maturity debt securities with maturities over 1 to 5 years
Held - to - maturity debt securities maturities total
Marketable Securities
Total
Aggregate notional amount of foreign exchange derivative financial instruments
Derivative Instruments, Gain (Loss) by Income Statement Location [Axis]
Income Statement and Other Comprehensive Income Location [Domain]
Other Comprehensive Income [Member]
Other Income Expense [Member]
US Treasury interest rate locks [Member]
Non Derivative Financial Instruments In Net Investment Hedge Relationships Gain Loss Recognized In Other Comprehensive Income Effective Portion Net
Non Derivative Financial Instruments In Net Investment Hedge Relationships Gain Loss Recognized In Income Net
Recognized in OCI
Recognized in OID
Aggregate fair value of net derivative liabilities
Concentration risk maximum exposure
Securities received as collateral
Total selected financial assets
Total selected financial liabilities
This category includes information about debt securities (such as bonds) that are issued by a either a domestic or foreign national government.
Asset write-offs and impairment charges
Purchases of common stock
Purchases of common stock
Long-term Debt, Type [Axis]
Long-term Debt, Type [Domain]
Senior Debt Obligations [Member]
Schedule of Finite Lived And Indefinite Lived Intangible Assets By Major Class Text Block
Cost reduction initiatives
Restructuring charges and implementation costs
Pristiq [Member]
Developed Europe [Member]
Developed Rest Of World [Member]
Emerging Markets [Member]
Gain (loss) net recorded in income from non-derivative financial instruments in net investment hedge relationships.
Gain (loss) net recorded in other comprehensive income from non-derivative financial instruments in net investment hedge relationships.
Private Equity Securities Owned Carried At Cost Or Equity
Private equity securities, carried at cost or equity method
This item represents the carrying amount on the entity's balance sheet of its investment in private equity securities accounted for under the cost and equity methods. The carrying amount for equity method investees is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment losses recognized. The original cost of the cost method investments may differ from the aggregate carrying amount due to various adjustments such as: (i) dividends received in excess of earnings after the date of investment that are considered a return of investment and therefore recorded as reductions to cost of the investment, or (ii) a series of operating losses of an investee or other factors which may indicate that a decrease in value of the investment has occurred which is other than temporary and should accordingly be recognized.
Fair value of long term foreign currency debt which is used as a hedging instrument.
Fair value of short term foreign currency borrowings which are used as hedging instruments.
U S Corporate Debt Guaranteed By Federal Deposit Insurance Corporation [Member]
This category includes information about debt securities issued by a domestic corporate business entity, which are guaranteed by the Federal Deposit Insurance Corporation.
Inventories
Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Period Increase Decrease
Currency translation adjustment and other
Schedule of Comprehensive Income
Indefinite-lived intangible assets brands
Indefinite-lived intangible assets in-process research and development
Indefinite-lived intangible assets trademarks
Short-term loans, carried at cost
Maturing in 2038 [Member]
Finite Lived and Indefinite Lived Intangible Assets [Line Items]
Footnotes to selected financial assets [Abstract]
King [Member]
Protonix [Member]
Asset impairments
Other Restructuring Costs
Additional Depreciation Asset Restructuring Abstract
Additional depreciation-asset restructuring
Business Acquisition Cost Of Acquired Entity Purchase Price Per Share
Acquisition Purchase Price Per Share
The per share amount of the total cost to be paid for the acquired entity.
Rapamune [Member]
Fragmin [Member]
Tygacil [Member]
Other (Income)/Deductions-Net [Text Block]
Schedule of Other (Income)/Deductions - Net [Text Block]
Schedule of other income deductions net.
Income Taxes
Other Income Deductions Net [Table]
Other (Income) Deductions - Net [Line Items]
Net loss/(gain) on asset disposals
Asset impairment charges and other charges
Certain asset impairment charges
Other, net
The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of intangible assets, other than goodwill, to fair value.
Interest expense
Interest income
Royalty - related income
Certain legal matters, net
Acquisition-related in-process research and development charges
Income from continuing operations attributable to Pfizer Inc.
Eps Denominator Abstract
EPS Denominator
Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions
Income Loss From Continuing Operations Available To Common Stockholders Basic
Income from continuing operations attributable to Pfizer Inc. common shareholders
This element represents the income or loss from continuing operations available to common stockholders which may also be defined as revenue less expenses and taxes from ongoing operations before extraordinary items and cumulative effects of changes in accounting principles, but after deduction of those portions of income or loss from continuing operations that are allocable to noncontrolling interests and preferred stock dividends declared or paid in the period, if any.
Pension And Other Postretirement Benefit Contributions Less Pension And Other Postretirement Benefit Expense
Benefit plan contributions (in excess of)/less than expense
The amount of cash or cash equivalents contributed during the reporting period by the entity to fund its pension plans and its non-pension postretirement benefit plans less the amount of pension and other postretirement benefit costs recognized during the period for defined benefit plans (periodic benefit costs include the following components: service cost, interest cost, expected return on plan assets, gain or loss on assets, prior service cost or credit, transition asset or obligation, and gain or loss due to settlements or curtailments).
Identifiable intangible assets, less accumulated amortization
Comprehensive Income [Abstract]
Schedule of Comprehensive Income [Table]
Purchase accounting significant impacts Inventory
Purchase accounting fair value adjustment related to inventory write-off
Significant impacts of purchase accounting for acquisitions related to inventory fair value adjustments.
Interest income
Royalty - related income
Net gain on asset disposals
Other, net
Short - term borrowings, carried at historical proceeds, as adjusted
Long-term debt, carried at historical proceeds, as adjusted
Short-term loans
Net interest expense
Other non-cash adjustments
Other non-cash adjustments
Financial assets measured at fair value on a recurring basis
Instruments used as offsets (assets)
Financial liabilities measured at fair value on a recurring basis
Instruments used as offsets (liabilities)
Available - for - sale debt securities maturities total
Less: Preferred stock dividends - net of tax
Segment profit/loss
Revenues by geographic area [Line Items]
Financial Instruments Disclosure [Text Block]
Fair value of long term debt
Schedule Of Revenues From External Customers And Long Lived Assets [Table]
Adoption of New Accounting Policies [Text Block]
Business Acquisition [Table]
Restructuring Charges [Line Items]
Schedule of Restructuring Charges [Table]
Available - for - sale debt securities [Member]
Financial Instruments [Line Items]
Fair Value Measurements [Table]
Weighted-average shares used to calculate earnings per common share:
Basis of Presentation [Abstract]
Acquisition of King Pharmaceuticals Inc [Abstract]
Other (Income)/Deductions-Net [Abstract]
Taxes on Income [Abstract]
Inventories [Abstract]
Goodwill and Other Intangible Assets [Abstract]
Pension and Postretirement Benefit Plans [Abstract]
Segment, Product and Geographic Information [Abstract]
Recording of Assets Acquired and Liabilities Assumed [Abstract]
Restructuring charges footnote information
Financial Assets Measured At Fair Value On Recurring Basis
Financial Liabilities Measured At Fair Value On Recurring Basis
Other Income Expense Net
Other deductions - net
Taxes and other current assets
Taxes and other noncurrent assets
Proceeds from redemptions and sales of short-term investments, net
Proceeds from sales and redemptions of short-term investments
Proceeds from redemptions and sales of long-term investments
Increase in short-term borrowings
Increase in short-term borrowings, net
Schedule Of Recognized Identifiable Assets Acquired And Liabilities Assumed As Part Of Business Combination [Text Block]
Schedule Of Components Of Comprehensive Income [Text Block]
Information about certain financial assets and liabiltiies [Text Block]
Contractual maturities of available-for-sale and held-to-maturity debt securities [Text Block]
Schedule Of Components Of Inventories [Text Block]
Schedule of net periodic benefit costs of pension and post retirement benefit plans [Text Block]
Schedule Of Earnings Per Share Basic By Common Class And Schedule Of Earnings Per Share Diluted By Common Class [Text Block]
Integration costs
Trading securities
Goodwill Other Changes
Other
Discontinued Operations [Abstract]
Basis of Presentation [Table]
Discontinued Operations [Table]
Discontinued Operations [Axis]
Discontinued Operations [Line Items]
King U S [Member]
King US [Member]
King International [Member]
Basis Of Presentation [Line Items]
Adjustments To Reconcile Net Income Loss Before Allocation To Noncontrolling Interests To Net Cash Provided By Used In Operating Activities [Abstract]
Adjustments to reconcile net income before allocation to noncontrolling interests to net cash provided by/(used in) operating activities:
Adoption of New Accounting Policies [Abstract]
Financial Instruments [Abstract]
Schedule of Revenues by Geographic Area [Text Block]
Employee Termination Costs
The charge against earnings in the period for known and estimated costs of termination benefits provided to current employees that are involuntarily terminated under a benefit arrangement associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, including costs or losses pertaining to an entity newly acquired in a business combination as defined by generally accepted accounting principles and costs associated with one-time termination benefits.
Employee termination costs
Other Financial Liabilities [Abstract]
Other financial liabilities
Discontinued operations:
Income from operations - net of tax
Gain on sale of discontinued operations - net of tax
Discontinued operations--net of tax
Liabilities of discontinued operations
Acquisitions, net of cash acquired
Acquisitions, net of cash acquired
Schedule Of Business Acquisition Included In Consolidated Statements Of Income [Text Block]
Schedule of business combination that is included in the condensed consolidated statement of income from the acquisition date.
Schedule of pro forma information related to the acquisition [Text Block]
Discontinued Operations [Text Block]
Schedule Of Disposal Groups Including Discontinued Operations Income Statement [Text Block]
Schedule for income statement, relating to disposal groups, including those classified as components of the entity (discontinued operations). May include the gain or loss recognized in the income statement and the income statement caption that includes that gain or loss, amounts of revenues and pretax profit or loss reported in discontinued operations, and the segment in which the disposal group was reported. Also includes the nature and amount of adjustments to amounts previously reported in discontinued operations such as resolution of contingencies arising from the disposal transaction or the operations of the component prior to disposal.
Schedule Of Disposal Groups Including Discontinued Operations Balance Sheet [Text Block]
Schedule for balance sheet relating to disposal groups, including those classified as components of the entity (discontinued operations). May include the classification and carrying value of the assets and liabilities comprising the disposal group, and the segment in which the disposal group was reported. Also includes the nature and amount of adjustments to amounts previously reported in discontinued operations such as resolution of contingencies arising from the disposal transaction or the operations of the component prior to disposal.
Acquisition purchase price paid
Business Acquisition Acquired Entity Common Shares Percent
Business acquisition additional payments
Represents the additional payments in cash for remaining outstanding shares for the acquisition.
Time period of King's operations included in parent's financial statements
Identifiable intangible assets, excluding in-process research and development
Business Combination Recognized Identifiable Other Assets Acquired And Liabilities Assumed Net
All other long - term assets and liabilities, net
The amount of all other assets and liabilities recognized as of the acquisition date.
Business Acquisition Narrative [Abstract]
Business Acquisition Narrative
Gross contractual amount receivable
Business Acquisition Included in Consolidated Statements of Income Abstract
Business Acquisition Included in Consolidated Statements of Income
Revenues of Acquiree since acquisition date
Revenues
Earnings or loss of acquiree since acquisition date
Loss from continuing operations attributable to Pfizer Inc. common shareholders
Business Acquisition Pro Forma Information
Business acquisition pro forma revenue
Revenues
Business acquisition pro forma income loss from continuing operations
Income from continuing operations attributable to Pfizer Inc. common shareholders
Business acquisition pro forma income loss from continuing operations per diluted share
Diluted earnings per share attributable to Pfizer Inc. common shareholders
Pro Forma Narrative Abstract
Pro Forma Narrative
Additional amortization of intangible assets
The additional amortization expense realted to the fair value of identifiable assets acquired included in the proforma results.
Additional depreciation expense
The additional depreciation expense related to the fair value adjustment to property, plant and equipment acquired included in the proforma results.
Fair Value By Measurement Frequency [Axis]
Fair Value Measurement Frequency [Domain]
Fair Value Measurements Recurring [Member]
Derivative assets measured at fair value on a recurring basis
Estimate of fair value disclosure [Member]
Fair Value Measurements Fair Value Hierarchy [Domain]
Fair Value by Fair Value Hierarchy Level [Axis]
Disposal Group Including Discontinued Operation Sale Price
Sale price for discontinued operation
Quarter which the sale of discontinued operation is expected to be completed
Discontinued operations - net of tax in Condensed Consolidated Statements of Income:
Assets of discontinued operations and other assets held for sale and Liabilities of discontinued operations in Condensed Consolidated Balance Sheets:
Revenues
Disposal Group Including Discontinued Operation Revenue
Pre-tax gain on sale of discontinued operations
The sale price of the discontinued operation.
Disposal Group Including Discontinued Operation Accounts Notes And Loans Receivable Net
Disposal Group Including Discontinued Operation Inventory
Disposal Group Including Discontinued Operation Current Deferred Tax And Other Assets
Taxes and other current assets
Disposal Group Including Discontinued Operation Property Plant And Equipment Net
Goodwill
Disposal Group Including Discontinued Operation Goodwill
Identifiable intangible assets
Disposal Group Including Discontinued Operation Noncurrent Deferred Tax And Other Assets
Taxes and other noncurrent assets
Current liabilities
Other liabilities
Assets of discontinued operations and other assets held for sale
Pre-tax income from discontinued operations
Provision for taxes
Income from discontinued operations--net of tax
Provision for income taxes
Provision for taxes
Provision for income taxes
Business Acquisition Measurement Period To Complete Allocation
Time period the allocation of King goodwill will be completed
Trademarks and other [Member]
Accounts receivable
Inventories
Other
Property, plant and equipment
Available - for - sale debt securities maturities over 10 years
Debt Securities Maturities Over Ten Years
Debt securities maturities over 10 years
This item represents debt securities which are expected to mature after ten years from the balance sheet date.
Debt Securities Maturities Within One Year
This item represents debt securities which are expected to mature within one year of the balance sheet date.
Debt securities maturities within 1 year
Debt Securities Maturities Over One To Five Years
This item represents debt securities which are expected to mature after one year and through five years from the balance sheet date.
Debt securities maturities over 1 to 5 years
Restructuring charges
Assets of discontinued operations and other assets held for sale
Liabilities of discontinued operations
Income from discontinued operations--net of tax
Net interest expense
Other deductions - net
Biopharmaceutical [Member]
Lipitor [Member]
Other current liabilities
Restructuring charges and certain acquisition-related costs
Percent of outstanding shares acquired
Costs Associated With Cost - Reduction Initiatives And Acquisition Activity [Abstract]
Schedule Of Business Acquisition Included In Condensed Consolidated Statements Of Income [Text Block]
Primary Care [Member]
Specialty Care And Oncology [Member]
Established Products and Emerging Markets [Member]
Animal Health and Consumer Healthcare [Member]
Nutrition and other business activities [Member]
Material Reconciling Items [Member]
Unallocated Amount To Segment [Member]
Purchase Accounting Adjustments [Member]
Acquisition-related costs [Member]
Certain significant items [Member]
Other unallocated [Member]
Restructuring charges and implementation costs associated with cost-reduction initiatives
Other charges
Animal Health [Member]
Consumer Healthcare [Member]
Nutrition [Member]
Pfizer Centre Source [Member]
Bene F I X [Member]
Aromasin [Member]
Aricept [Member]
B M P 2 [Member]
Total reportable segments [Member]
Other Products [Member]
Discontinued Operations [Domain]
Goodwill Unallocated [Member]
To be Allocated [Member]
Percentage Of Indefinitelived Intangible Asset Unamortized Costs By Segment
Percentage Of Finitelived Intangible Asset Amortized Cost By Segment
Percentage Of Finite-lived Intangible Asset Amortized Cost By Segment
Percentage Of Indefinite-lived Intangible Asset Unamortized Costs By Segment
Research and Development [Member]
Business Combination Purchase Accounting Adjustment Restructuring
This element represents the amount of purchase accounting adjustments related to restructuring charges in a business combination.
Purchase accounting adjustment for restructuring and integration
Purchase accounting adjustment for amortization of identifiable intangible assets acquired
Inventory Supply Years
Inventory supply
This item represents inventories supply period that is generally consistent with the normal operating cycle of such inventory.
Purchase accounting adjustment for acquisition-date inventory estimated to have been sold, fair value
Earnings
Total assets
Federal Home Loan Mortgage Corporation and Federal National Mortgage Association asset-backed securities [Member]
Foreign currency debt used as hedging instrument [Member]
Foreign currency borrowings used as hedging instruments [Member]
Pfizer CentreSource [Member]
US government Federal Deposit Insurance Corporation guaranteed debt [Member]
In Process Research And Development [Member]
Represents purchased research and development assets that are acquired in a business combination.
Legal Proceedings and Contingencies [Abstract]
Legal Proceedings and Contingencies [Text Block]
Total fair value of consideration transferred, net of cash acquired
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed In Process Research And Development
In-process research and development
The amount of in process research and development recognized as of the acquisition date.
BeneFIX [Member]
Detrol / Detrol LA [Member]
ReFacto AF/ Xyntha [Member]
BMP2 [Member]
Prevnar / Prevenar (7-valent) [Member]
Elimination Of Intangible Asset Amortization
Elimination of intangible asset amortization
The elimination of historical intangible asset amortization expense included in the proforma results.
Elimination Of Acquisition Costs
Adjustment for acquisition-related costs
The elimination of costs incurred which are directly attributable to the acquisition and do not have a continuing impact on the Company.
Legal Proceedings and Contingencies [Line Items]
Cumulative Product Liabilty Accrual Expense
Cumulative product liability charges
The cumulative amount of loss reported during the period pertaining to product liability.
Product liability charge for the minimum expected costs to resolve outstanding actions
Legal Proceedings and Contingencies [Table]
Product liability charge
Represents the percent of common shares acquired.
For the disposal group, including a component of the entity (discontinued operation), represents a) The deferred tax assets (net of any valuation allowances), which result from applying the applicable tax rate to net deductible temporary differences and carryforwards pertaining to each jurisdiction to which the entity is obligated to pay income tax. A deductible temporary difference is a difference between the tax basis and the carrying amount of an asset or liability in the financial statements prepared in accordance with generally accepted accounting principles that will result in deductible amounts for tax purposes in future periods if there is sufficient tax-basis income to enable the deduction to be taken that are expected to be realized or consumed within one year or the normal operating cycle, if longer, and b) Carrying amount of other assets not otherwise specified in the taxonomy that are expected to be realized or consumed within one year or the normal operating cycle, if longer.
For the disposal group, including a component of the entity (discontinued operation), represents a) The deferred tax assets (net of any valuation allowances), which result from applying the applicable tax rate to net deductible temporary differences and carryforwards pertaining to each jurisdiction to which the entity is obligated to pay income tax. A deductible temporary difference is a difference between the tax basis and the carrying amount of an asset or liability in the financial statements prepared in accordance with generally accepted accounting principles that will result in deductible amounts for tax purposes in future periods if there is sufficient tax-basis income to enable the deduction to be taken, and b) Carrying amount as of the balance sheet date of assets not otherwise specified, and which are expected to be realized or consumed after one year or beyond the normal operating cycle, if longer. For an unclassified balance sheet, represents both current and noncurrent other assets.
The percentage of amortized cost of finite-lived intangible assets by segment.
The percentage of unamortized cost of indefinite-lived intangible assets by segment.
Corporate [Member]
Fair value inputs Level 3 [Member]
Primary Care operating segment [Member]
Worldwide Research and Development [Member]
Specialty Care and Oncology operating segment [Member]
Established Products and Emerging Markets operating segment [Member]
Animal Health and Consumer Healthcare operating segment [Member]
Specialty Care [Member]
Oncology [Member]
Established Products [Member]
Effexor XR [Member]